Ticker Symbol: TOS/TSX
Shares Outstanding: 46 244 102
QUEBEC CITY, Sept. 27 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces the sale of a 125L Ozone Sterilizer to the last remaining hospital
participating in the Referral Site Program. This sale concludes the program.
A Canadian leader in trauma care for more than 35 years, this hospital
has served as a tertiary trauma center, offering highly specialized care
within its province, since 1992. Owing to its expertise both in microbiology
and infection prevention, this center is also considered a reference in
"Our primary goal was to cut down on the use of Ethylene Oxide for low
temperature sterilization in compliance with the Canadian regulation(1)
concerning the reduction of emission of this toxic gas", stated the person in
charge of central sterilization at the hospital at the time of trial of the
125L Ozone Sterilizer. "Our personnel have been pleased with its simplicity of
operation. Using ozone sterilization has lead to substantial savings, but also
to a more effective material distribution, since this method is faster."
"Ozone sterilization answers many needs in sterilization, such as
reducing the use of pollutants and toxic gases like Ethylene Oxide. This sale
is a concrete example of that." Stated Jocelyn Vézina, CEO for TSO3 Inc. "We
are pleased to see such a proactive and renowned hospital become a satisfied
user and a buyer of ozone sterilization."
As a reminder, Environment Canada has asked hospitals to reduce their
Ethylene Oxide releases in the environment by 99%.
(1) Guidelines for the Reduction of Ethylene Oxide Releases from
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology whit high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
TSO3 currently has more than 65 employees, about half of whom work in the
sales and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications & IR, (418) 651-0003, Ext. 237, email@example.com; Source: TSO3